Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples...
Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity
About this item
Full title
Author / Creator
Hong, Tae Hee , Cha, Hongui , Shim, Joon Ho , Lee, Boram , Chung, Jongsuk , Lee, Chung , Kim, Nayoung K D , Choi, Yoon-La , Hwang, Soohyun , Lee, Yoomi , Park, Sehhoon , Jung, Hyun Ae , Kim, Ji-Yeon , Park, Yeon Hee , Sun, Jong-Mu , Ahn, Jin Seok , Ahn, Myung-Ju , Park, Keunchil , Lee, Se-Hoon and Park, Woong-Yang
Publisher
England: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
BackgroundTumor mutational burden (TMB) measurement is limited by low tumor purity of samples, which can influence prediction of the immunotherapy response, particularly when using whole-exome sequencing-based TMB (wTMB). This issue could be overcome by targeted panel sequencing-based TMB (pTMB) with higher depth of coverage, which remains unexplor...
Alternative Titles
Full title
Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_47c869a682954a4b8cfd17be6e159c27
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_47c869a682954a4b8cfd17be6e159c27
Other Identifiers
ISSN
2051-1426
E-ISSN
2051-1426
DOI
10.1136/jitc-2020-001199
